Increase in Therapeutic Index of Doxorubicin and Vinblastine by Aptameric Oligonucleotide in Human T Lymphoblastic Drug-Sensitive and Multidrug-Resistant Cells

Abstract

Aptameric GT oligomers are a new class of potential anticancer molecules that inhibit the growth of human cancer cell lines by binding to specific nuclear proteins. We demonstrated that an aptameric GT oligonucleotide increased the therapeutic index of doxorubicin and vinblastine in T lymphoblastic drug-sensitive and multidrug-resistant (MDR) cells. The doxorubicin ID₅₀ decreased 6.5-fold by coadministration of 1 μM GT to CCRF-CEM cells and by 24-fold by coadministration of 0.75μ M GT to CEM-VLB300 cells. In CEM-VLB300 cells, the vinblastine ID₅₀ decreased 11-fold by coadministration of 0.5 μM GT. Control CT sequence did not potentiate the drugs in either CCRF-CEM or CEM-VLB300 cells. The ability of GT to bind to specific nuclear proteins in cancer cells related to the increase in the therapeutic index of doxorubicin and vinblastine. No cooperation was detected by the administration of GT oligomer together with doxorubicin to rat differentiated thyroid FRTL-5 cells and to normal human lymphocytes. These cells did not show binding of GT to the specific nuclear proteins, and they were not sensitive to the cytotoxic action of the GT sequence. Drug potentiation by GT not involving normal human lymphocytes might be exploited to develop a more selective treatment of drug-sensitive and MDR tumors.